Speaker :

Dr. Rakesh Pinninti, Medical Oncologist, Hyderabad

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised,  placebo-controlled, phase 3 study                              

Author: Sandra M Swain

 Citation: Lancet Oncol. 2020 Apr;21(4):519-530.

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

Author: Aranzazu Fernandez-Martinez

 Citation: Journal of Clinical Oncology 38, no. 35 (December 10 2020) 4184-4193